Central nervous system delivery of large molecules: Challenges and new frontiers for intrathecally administered therapeutics

Expert Opinion on Drug Delivery

Volumn 7, Issue 3, 2010, Pages 285-293

  Soderquist, Ryan G ^a   Mahoney, Melissa J ^a  

^a UCB 450   (United States)

Author keywords

Bloodbrain barrier; Central nervous system; Intrathecal; Microparticle; PEGylation; PLGA

Indexed keywords

DNA; MACROGOL; PLASMID DNA; POLYLACTIC ACID; PROTEIN;

BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STABILITY; GENE TARGETING; HUMAN; INFUSION PUMP; MACROMOLECULE; MICROENCAPSULATION; MOLECULAR STABILITY; NONHUMAN; REVIEW;

BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEMS; HUMANS; INJECTIONS, SPINAL; PHARMACOKINETICS;

EID: 77749283336     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903540205     Document Type: Review

References (95)

1. Misra A, Ganesh S, Shahiwala A, et al. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci 2003;6(2):252-73
2. Martin-Villalba A, Okuducu AF, von Deimling A. The evolution of our understanding on glioma. Brain Pathol 2008;18(3):455-63
3. Prince DA, Parada I, Scalise K, et al. Epilepsy following cortical injury: cellular and molecular mechanisms as targets for potential prophylaxis. Epilepsia 2009;50:30-40
4. Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia how to move forward? Neurology 2009;72(4):368-74
5. Strecker K, Schwarz J. Parkinson's disease: emerging pharmacotherapy. Expert Opin Emerging Drugs 2008;13(4):573-91
6. Biran Y, Masters CL, Barnham KJ, et al. Pharmacotherapeutic targets in Alzheimer's disease. J Cell Mol Med 2009;13(1):61-86
7. Vernino S, Geschwind M, Boeve B. Autoimmune encephalopathies. Neurologist 2007;13(3):140-7
8. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev Neurosci 2005;6(7):521-32
9. Nagahara AH, Merrill DA, Coppola G, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 2009;15:331-7
10. Dawbarn D, Allen SJ. Neurotrophins and neurodegeneration. Neuropathol Appl Neurobiol 2003;29(3):211-30
11. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest 2000;117(4):1162-72
12. Walker D, Lue LF. Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions. Curr Neuropharmacol 2007;5(4):232-43
13. Pettingill LN, Minter RL, Shepherd RK. Schwann cells genetically modified to express neurotrophins promote spiral ganglion neuron survival in vitro. Neuroscience 2008;152(3):821-8
14. Blesch A, Tuszynski MH. Transient growth factor delivery sustains regenerated axons after spinal cord injury. J Neurosci 2007;27(39):10535-45
15. Yao MZ, Gu JF, Wang JH, et al. Interleukin-2 gene therapy of chronic neuropathic pain. Neuroscience 2002;112(2):409-16
16. Sloane E, Ledeboer A, Seibert W, et al. Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental multiple sclerosis. Brain Behav Immun 2009;23(1):92-100
17. Patel MM, Goyal BR, Bhadada SV, et al. Getting into the brain approaches to enhance brain drug delivery. CNS Drugs 2009;23(1):35-58
18. Tosi G, Costantino L, Ruozi B, et al. Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin Drug Deliv 2008;5(2):155-74
19. Lagarce F, Benoit JP. Sustained release formulations for spinal drug delivery. J Drug Deliv Sci Technol 2004;14(5):331-43
20. Smith HS, Deer TR, Staats PS, et al. Intrathecal drug delivery. Pain Physician 2008; Opiod Special Issue(11):S89-S104
21. Goss JR, Goins WF, Glorioso JC. Gene therapy applications for the treatment of neuropathic pain. Expert Rev Neurother 2007;7(5):487-506
22. Gallagher RM. Intrathecal drug delivery for chronic back pain: better science for clinical innovation. Pain Med 2004;5(1):1-3
23. Rosenblum LY, Johnson RC, Schmahai TJ. Preclinical safety evaluation of recombinant human interleukin-10. Regul Toxicol Pharmacol 2002;35(1):56-71
24. Lin JH. CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr Drug Metab 2008;9(1):46-59
25. Rambeck B, Jurgens UH, May TW, et al. Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Epilepsia 2006;47(4):681-94
26. Sharma HS, Johanson CE. Blood-cerebrospinal fluid barrier in hyperthermia. Neurobiology of hyperthermia. Elsevier Science Bv, Amsterdam; 2007. p. 459-78
27. Krewson CE, Klarman ML, Saltzman WM. Distribution of nerve growth-factor following direct delivery to brain interstitium. Brain Res 1995;680(1-2):196-206
28. Shen DD, Artru AA, Adkison KK. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 2004;56(12):1825-57
29. Newcomb R, Abbruscato TJ, Singh T, et al. Bioavailability of Ziconotide in brain: influx from blood, stability, and diffusion. Peptides 2000;21(4):491-501
30. Kandel ER, Schwartz JH, Jessell TM. Principles of neural science. 4th edition. McGraw-Hill, New York; 2000
31. Abbott NJ. Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem Int 2004;45(4):545-52
32. Greitz D, Hannerz J. A proposed model of cerebrospinal fluid circulation: observations with radionuclide cisternography. Am J Neuroradiol 1996;17(3):431-8
33. Whittlesey KJ, Shea LD. Delivery systems for small molecule drugs, proteins, and DNA: the neuroscience/biomaterial interface. Exp Neurol 2004;190(1):1-16
34. Wieseler-Frank J, Jekich BM, Mahoney JH, et al. A novel immune-to-CNS communication pathway: Cells of the meninges surrounding the spinal cord CSF space produce proinflammatory cytokines in response to an inflammatory stimulus. Brain Behav Immun 2007;21(5):711-8
35. Mercier F, Hatton GI. Immunocytochemical basis for a meningeo-glial network. J Comp Neurol 2000;420(4):445-65
36. Tsutsami Y, Tsunoda S-I, Kamada H, et al. PEGylation of Interleukin-6 effectively increases its thrombopoietic potency. Thromb Haemost 1997;77(1):168-73
37. Basu A, Yang K, Wang ML, et al. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug Chem 2006;17(3):618-30
38. Ramon J, Saez V, Baez R, et al. PEGylated interferon-alpha 2b: a branched 40K polyethylene glycol derivative. Pharm Res 2005;22(8):1374-86
39. Bailon P, Berthold W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm Sci Technol Today 1998;1(8):352-6
40. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002;54(4):459-76
41. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10(21-24):1451-8
42. Harris MJ, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40(7):539-51
43. Koumenis IL, Shahrokh Z, Leong S, et al. Modulating pharmacokinetics of an anti-interleukin-8 F(ab')(2) by amine-specific PEGylation with preserved bioactivity. Int J Pharm 2000;198(1):83-95
44. Clark R, Olson K, Fuh G, et al. Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem 1996;271(36):21969-77
45. Francis GE, Fisher D, Delgado C, et al. PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques. Int J Hematol 1998;68:1-18
46. Molineux G. Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy 2003;23(8 Pt 2):3S-8S
47. Dhalluin C, Ross A, Leuthold LA, et al. Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha(2a) and its individual positional isomers. Bioconjug Chem 2005;16(3):504-17
48. Stroh M, Zipfel WR, Williams RM, et al. Multiphoton microscopy guides neurotrophin modification with poly (ethylene glycol) to enhance interstitial diffusion. Nat Mater 2004;3(7):489-94
49. Dang W, Colvin MO, Brem H, et al. Covalent coupling of methotrexate to dextran enhances the penetration of cytotoxicity into a tissue-like matrix. Cancer Res 1994;54:1729-35
50. Ankeny DP, McTigue DM, Guan Z, et al. Pegylated brain-derived neurotrophic factor shows improved distribution into the spinal cord and stimulates locomotor activity and morphological changes after injury. Exp Neurol 2001;170(1):85-100
51. Greenwald RB, Yang K, Zhao H, et al. Controlled release of proteins from their poly(ethylene glycol) conjugates: drug delivery systems employing 1,6-elimination. Bioconjug Chem 2003;14(2):395-403
52. Scarisbrick IA, Towner MD, Isackson PJ. Nervous system-specific expression of a novel serine protease: regulation in the adult rat spinal cord by excitotoxic injury. J Neurosci 1997;17(21):8156-68
53. Polfliet MMJ, Goede PH, van Kesteren-Hendrikx EML, et al. A method for the selective depletion of perivascular and meningeal macrophages in the central nervous system. J Neuroimmunol 2001;116(2):188-95
54. McMenamin PG, Wealthall RJ, Deverall M, et al. Macrophages and dendritic cells in the rat meninges and choroid plexus: three-dimensional localisation by environmental scanning electron microscopy and confocal microscopy. Cell Tissue Res 2003;313(3):259-69
55. Soderquist RG, Milligan ED, Sloane EM, et al. PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution. J Biomed Mater Res A 2009;91(3):719-29
56. Soderquist RG, Milligan ED, Harrison JA, et al. PEGylation of interleukin-10 for the mitigation of enhanced pain states. J Biomed Mater Res A 2009. Published online 18 Sep 2009. Available at http://dx.doi.org/10.1002/jbm. a.32611
57. Radler JO, Koltover I, Salditt T, et al. Structure of DNA-cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes. Science 1997;275(5301):810-4
58. Park JH, Lee S, Kim JH, et al. Polymeric nanomedicine for cancer therapy. Prog Polym Sci 2008;33(1):113-37
59. Boussif O, Lezoualch F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo-polyethylenimine. Proc Natl Acad Sci USA 1995;92(16):7297-301
60. Shi L, Tang GP, Gao SJ, et al. Repeated intrathecal administration of plasmid DNA complexed with polyethylene glycol-grafted polyethylenimine led to prolonged transgene expression in the spinal cord. Gene Ther 2003;10(14):1179-88
61. Meuli-Simmen C, Liu Y, Yeo TT, et al. Gene expression along the cerebral-spinal axis after regional gene delivery. Hum Gene Ther 1999;10(16):2689-700
62. Milligan ED, Soderquist RG, Malone SM, et al. Intrathecal polymer-based interleukin-10 gene delivery for neuropathic pain. Neuron Glia Biol 2006;2(4):293-308
63. Tang GP, Zeng JM, Gao SJ, et al. Polyethylene glycol modified polyethylenimine for improved CNS gene transfer: effects of PEGylation extent. Biomaterials 2003;24(13):2351-62
64. Wang X, Wang CY, Zeng JM, et al. Gene transfer to dorsal root ganglia by intrathecal injection: effects on regeneration of peripheral nerves. Mol Ther 2005;12(2):314-20
65. Godbey WT, Wu KK, Mikos AG. Poly (ethylenimine)-mediated gene delivery affects endothelial cell function and viability. Biomaterials 2001;22(5):471-80
66. Fischer D, Li YX, Ahlemeyer B, et al. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 2003;24(7):1121-31
67. Tiera MJ, Winnik FM, Fernandes JC. Synthetic and natural polycations for gene therapy: state of the art and new perspectives. Curr Gene Ther 2006;6(1):59-71
68. Tang GP, Guo HY, Alexis F, et al. Low molecular weight polyethylenimines linked by beta-cyclodextrin for gene transfer into the nervous system. J Gene Med 2006;8(6):736-44
69. Arote R, Kim TH, Kim YK, et al. A biodegradable poly(ester amine) based on polycaprolactone and polyethylenimine as a gene carrier. Biomaterials 2007;28(4):735-44
70. Edlund U, Albertsson AC. Degradable polymer microspheres for controlled drug delivery. Degradable Aliphatic Polyesters 2002;157:67-112
71. Birnbaum DT, Brannon-Peppas L. Microparticle drug delivery systems. In: Brown DM, editor, Drug delivery systems in cancer therapy. Humana Press Inc., Totowa, NJ; 2003. p. 117-35
72. Kumar M, Bakowsky U, Lehr CM. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials 2004;25(10):1771-7
73. Barman SP, Lunsford L, Chambers P, et al. Two methods for quantifying DNA extracted from poly(lactide-co-glycolide) microspheres. J Control Release 2000;69(3):337-44
74. Tinsley-Bown AM, Fretwell R, Dowsett AB, et al. Formulation of poly(D,L-lactic-co-glycolic acid) microparticles for rapid plasmid DNA delivery. J Control Release 2000;66(2-3):229-41
75. Cohen S, Yoshioka T, Lucarelli M, et al. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res 1991;8(6):713-20
76. Liu Y, Deng XM. Influences of preparation conditions on particle size and DNA-loading efficiency for poly(DL-lactic acid-polyethylene glycol) microspheres entrapping free DNA. J Control Release 2002;83(1):147-55
77. Sendil D, Bonney IM, Carr DB, et al. Antinociceptive effects of hydromorphone, bupivacaine and biphalin released from PLGA polymer after intrathecal implantation in rats. Biomaterials 2003;24(11):1969-76
78. Lagarce F, Renaud P, Faisant N, et al. Baclofen-loaded microspheres: preparation and efficacy testing in a new rabbit model. Eur J Pharm Biopharm 2005;59(3):449-59
79. Lagarce F, Faisant N, Desfontis JC, et al. Baclofen-loaded microspheres in gel suspensions for intrathecal drug delivery: in vitro and in vivo evaluation. Eur J Pharm Biopharm 2005;61(3):171-80
80. Milligan ED, Langer SJ, Sloane EM, et al. Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. Eur J Neurosci 2005;21(8):2136-48
81. Berg SL, Balis FM, McCully CL, et al. Pharmacokinetics of peg-l-asparaginase and plasma and cerebrospinal-fluid l-asparagine concentrations in the rhesus-monkey. Cancer Chemother Pharmacol 1993;32(4):310-4
82. Hinds KD, Campbell KM, Holland KM, et al. PEGylated insulin in PLGA microparticles. In vivo and in vitro analysis. J Control Release 2005;104(3):447-60
83. Gander B, Meinel L, Walter E, et al. Polymers as a platform for drug delivery: reviewing our current portfolio on poly (lactide-co-glycolide) (PLGA) microspheres. Chimia 2001;55(3):212-7
84. Wang CY, Wang S. Adeno-associated virus inverted terminal repeats improve neuronal transgene expression mediated by baculoviral vectors in rat brain. Hum Gene Ther 2005;16(10):1219-26
85. Kaneda Y, Tabata Y. Non-viral vectors for cancer therapy. Cancer Sci 2006;97(5):348-54
86. Anderson WF. Human gene therapy. Nature 1998;392(6679):25-30
87. Milligan ED, Sloane EM, Langer SJ, et al. Repeated intrathecal injections of plasmid DNA encoding interleukin-10 produce prolonged reversal of neuropathic pain. Pain 2006;126(1-3):294-308
88. Singh M, Briones M, Ott G, et al. Cationic microparticles: a potent delivery system for DNA vaccines. Proc Natl Acad Sci USA 2000;97(2):811-6
89. Wang DQ, Robinson DR, Kwon GS, et al. Encapsulation of plasmid DNA in biodegradable poly(D,L-lactic-co-glycolic acid) microspheres as a novel approach for immunogene delivery. J Control Release 1999;57(1):9-18
90. Li Y, Wang J, Lee CGL, et al. CNS gene transfer mediated by a novel controlled release system based on DNA complexes of degradable polycation PPE-EA: a comparison with polyethylenimine/DNA complexes. Gene Ther 2004;11(1):109-14
91. Luo D, Woodrow-Mumford K, Belcheva N, et al. Controlled DNA delivery systems. Pharm Res 1999;16(8):1300-8
92. Lunsford L, McKeever U, Eckstein V, et al. Tissue distribution and persistence in mice of plasmid DNA encapsulated in a PLGA-based microsphere delivery vehicle. J Drug Target 2000;8(1):39-50
93. Ward AB, Kadies M. The management of pain in spasticity. Disabil Rehabil 2002;24(8):443-53
94. Plassat R, Verbe BP, Menei P, et al. Treatment of spasticity with intrathecal baclofen administration: long-term follow-up, review of 40 patients. Spinal Cord 2004;42(12):686-93
95. Delhaas EM, Beersen N, Redekop WK, et al. Long-term outcomes of continuous intrathecal baclofen infusion for treatment of spasticity: a prospective multicenter follow-up study. Neuromodulation 2008;11(3):227-36